A Narrative Review of the OX40-OX40L Pathway as a Potential Therapeutic Target in Atopic Dermatitis: Focus on Rocatinlimab and Amlitelimab.

Abdelhalim, Asaad; Yilmaz, Orhan; Elshaikh Berair, Mohamed; Torres, Tiago

http://hdl.handle.net/10400.16/3785

Use this identifier to reference this record.

Name:	Description:	Size:	Format:
13555_2024_Article_1308.pdf		345.16 KB	Adobe PDF	Download

Send Feedback

Authors

Abdelhalim, Asaad

Yilmaz, Orhan

Elshaikh Berair, Mohamed

Torres, Tiago

Abstract(s)

Atopic dermatitis (AD) is a common chronic inflammatory skin disease involving complex immune dysregulation, including the OX40-OX40L pathway. Rocatinlimab and amlitelimab, monoclonal antibodies targeting OX40 and OX40L, respectively, have shown promise in treating moderate-to-severe AD. Both therapies have demonstrated significant efficacy in reducing disease severity, with favorable safety profiles and no serious treatment-related adverse events. Both treatments outperformed placebo across key clinical endpoints, including skin clearance and symptom reduction, highlighting their potential as effective AD therapies. Although initial results are promising, further research is needed to evaluate the long-term effects, durability of response, and safety of these treatments. These findings support the therapeutic potential of targeting the OX40-OX40L pathway in AD, providing new options for patients with moderate-to-severe disease, with ongoing trials necessary to confirm their sustained benefits.

Keywords

Amlitelimab Atopic dermatitis OX40 OX40-OX40L Rocatinlimab

URI

http://hdl.handle.net/10400.16/3785

Citation

Abdelhalim A, Yilmaz O, Elshaikh Berair M, Torres T. A Narrative Review of the OX40-OX40L Pathway as a Potential Therapeutic Target in Atopic Dermatitis: Focus on Rocatinlimab and Amlitelimab. Dermatol Ther (Heidelb). 2024 Dec;14(12):3197-3210. doi: 10.1007/s13555-024-01308-8. Epub 2024 Nov 20. PMID: 39565527; PMCID: PMC11604912.